These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8549378)

  • 1. In vitro activity and clinical efficacy of ciprofloxacin in otorhinolaryngeal infections.
    Speciale A; Blandino G; Caccamo F; Serra A
    Drugs; 1995; 49 Suppl 2():403-5. PubMed ID: 8549378
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic and clinical studies of T-3761 in otorhinolaryngeal infections.
    Shinkawa A; Kimura H; Sakai M; Miyake H
    Drugs; 1995; 49 Suppl 2():401-2. PubMed ID: 8549377
    [No Abstract]   [Full Text] [Related]  

  • 3. [Ciprofloxacin in the treatment of chronic bacterial prostatitis].
    Trapeznikova MF; Savitskaia KI; al-Suri A; Nekhorosheva AG; Abramian NS; Nasonov VN
    Urol Nefrol (Mosk); 1995; (5):20-3. PubMed ID: 8571477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antimicrobial activity of ciprofloxacin and netilmicin compared to various antibiotics in Lome, Togo].
    Dagnra AY; Prince-David M; Hounkpati A
    Sante; 2001; 11(1):63-6. PubMed ID: 11313234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinolones in dermatology.
    Sable D; Murakawa GJ
    Dis Mon; 2004 Jul; 50(7):381-94. PubMed ID: 15280869
    [No Abstract]   [Full Text] [Related]  

  • 6. Changes in susceptibility to ciprofloxacin in a community in northern Israel.
    Cahana Z; Gilboa A; Raz R
    Drugs; 1995; 49 Suppl 2():173-4. PubMed ID: 8549292
    [No Abstract]   [Full Text] [Related]  

  • 7. [Fluoroquinolones--antibacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs].
    Naumann P; Dopp C
    Internist (Berl); 1989 Jan; 30(1):20-31. PubMed ID: 2646237
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro antimicrobial activity of CP-99,219, a new 7-azabicyclonaphthyridone.
    Jones RN
    Drugs; 1995; 49 Suppl 2():205-7. PubMed ID: 8549305
    [No Abstract]   [Full Text] [Related]  

  • 9. Limiting the use of the quinolones--ciprofloxacin and ofloxacin.
    Poole MD
    Ear Nose Throat J; 1992 Oct; 71(10):466. PubMed ID: 1425367
    [No Abstract]   [Full Text] [Related]  

  • 10. An assessment of ciprofloxacin per os in treatment of serious infections.
    Dellamonica P; Bernard E; Etesse H; Garraffo R; Beziau H
    Chemioterapia; 1987 Jun; 6(2 Suppl):391-4. PubMed ID: 3509456
    [No Abstract]   [Full Text] [Related]  

  • 11. Initial clinical experience with clinafloxacin in the treatment of serious infections.
    Tack KJ; McGuire NM; Eiseman IA
    Drugs; 1995; 49 Suppl 2():488-91. PubMed ID: 8549411
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of ciprofloxacin nonsusceptible urinary tract infections with ciprofloxacin.
    Jeffres MN; Shuster JE; Barclay SM
    Ann Pharmacother; 2011 Jun; 45(6):824-5. PubMed ID: 21666093
    [No Abstract]   [Full Text] [Related]  

  • 13. Ciprofloxacin as treatment for conjunctivitis.
    Chisari G; Reibaldi M
    J Chemother; 2004 Apr; 16(2):156-9. PubMed ID: 15216950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antibacterial activities of broad spectrum quinolones against clinical bacterial isolates.
    Matsumoto T; Tateda K; Ishii Y; Ohno A; Miyazaki S; Yamaguchi K
    Drugs; 1995; 49 Suppl 2():219-21. PubMed ID: 8549309
    [No Abstract]   [Full Text] [Related]  

  • 15. Ciprofloxacin in the treatment of serious infections in systemic lupus erythematosus.
    Oh HM; Koh WH; Boey ML
    Drugs; 1995; 49 Suppl 2():486-7. PubMed ID: 8549410
    [No Abstract]   [Full Text] [Related]  

  • 16. Ciprofloxacin versus placebo in the treatment of acute bacterial diarrhea.
    Pichler H; Diridl G; Stickler K; Wolf D
    Chemioterapia; 1987 Jun; 6(2 Suppl):490-1. PubMed ID: 3334608
    [No Abstract]   [Full Text] [Related]  

  • 17. A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin.
    Sánchez-Recio MM; Colino CI; Sánchez-Navarro A
    J Antimicrob Chemother; 2000 Mar; 45(3):321-8. PubMed ID: 10702551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of ciprofloxacin as a representative of veterinary fluoroquinolones in susceptibility testing.
    Riddle C; Lemons CL; Papich MG; Altier C
    J Clin Microbiol; 2000 Apr; 38(4):1636-7. PubMed ID: 10747156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.
    Ravizzola G; Pinsi G; Pirali F; Colombrita D; Foresti I; Peroni L; Turano A
    Drugs Exp Clin Res; 1989; 15(1):11-5. PubMed ID: 2743869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of the efficacy and tolerability of miocamycin in the treatment of otorhinololaryngologic infection by sensitive micro-organisms].
    Bellioni P; Di Luzio Paparatti U; Salvinelli F; Artuso A
    Riv Eur Sci Med Farmacol; 1987 Sep; 9(3):293-8. PubMed ID: 3509888
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.